

November 9, 2018



Interpace Diagnostics to Participate in 9th Annual Craig-Hallum Alpha Select Conference

PARSIPPANY, NJ, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDYG) announced today that the Company has been invited to participate at the 9th Annual Craig-Hallum Alpha Select Conference to be held on November 15, 2018 at the Sheraton New York Times Square Hotel. Companies, such as Interpace, have been individually selected by the Craig-Hallum research team based on several factors including above average growth prospects, attractive business models, competitive advantage, unappreciated value and strong management teams. The Alpha Select List companies will be presented to top institutional investors and analysts from across the country.

Interpace will host one-on-one meetings with investors at the conference throughout the day. To schedule a one-on-one meeting with management, please contact our representatives at Edison Advisors or your Craig-Hallum representative.

Conference Details:

Title: 9th Annual Craig-Hallum Alpha Select Conference

Date: Thursday, November 15, 2018

Location: Sheraton New York Times Square Hotel

811 7th Avenue

New York, NY 10019

About Interpace Diagnostics Group, Inc.

Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® (now ThyGeNEXT™) for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently being "soft launched" with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US and over time can progress to esophageal cancer. The Company's data base includes data from over 45,000 patients who have been tested using the Company's current products, including over 25,000 molecular tests for thyroid nodules. Interpace has been

designated by the 2017 edition of *CIO Applications* as one of the top 20 companies for providing bioinformatics solutions. Interpace's mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace's website at www.interpacediagnostics.com.

About Craig-Hallum Capital Group, LLC

Craig-Hallum is an employee-owned, idea-driven research, trading and investment banking firm focused on emerging growth companies and institutional investors. The firm provides research, sales and trading for institutional investors, while the investment banking group provides companies with financing alternatives through initial public offerings, convertible securities and private placements. For more information on the Alpha Select Conference, please contact chconference@craig-hallum.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's ability to adequately finance the business, its ability to restructure its liabilities and other obligations, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing.. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS:

Interpace Diagnostics
Edison Advisors - Investor Relations
Joseph Green
(646) 653 – 7030
jgreen@edisongroup.com



Source: Interpace Diagnostics Group, Inc.